ADAMTSL3: A Promising Drug Target and Biomarker for ALS-Like Synaptic Transmission

Target Name: ADAMTSL3

NCBI ID: G57188

ADAMTSL3

ADAMTSL3: A Promising Drug Target and Biomarker for ALS-Like Synaptic Transmission

Introduction

Amyloid-like synaptic transmission (AS) is a well-established pathological mechanism in the development of neurodegenerative diseases, including Alzheimer's disease (AD). The abnormal accumulation of amyloid peptides and their disruptive impact on synaptic function have been implicated in the progression of these disorders. The study of AS and its underlying mechanisms has led to the discovery of numerous potential drug targets. One such target is ADAMTSL3, a protein that plays a critical role in the regulation of synaptic plasticity and is aberrantly expressed in various neurodegenerative diseases. In this article, we will discuss ADAMTSL3 as a drug target and biomarker for ALS-like synaptic transmission.

The Extent of Synaptic Transmission

Synaptic transmission refers to the exchange of information between neurons through their synapses. The communication between neurons is critical for learning, adaptation, and memory formation. The complex network of synapses in the brain is regulated by numerous factors, including the levels of neurotransmitters, ion channels, and signaling pathways.

In synaptic transmission, Amyloid-like peptides (ALPs) are generated from the neurotransmitter acetylcholine. These peptides then interact with the protein ADAMTSL3, leading to the regulation of synaptic plasticity and the modulation of neurotransmitter release. The accumulation of ALPs in the synapse can disrupt the proper function of the neurotransmitter receptor, leading to changes in the levels of neurotransmitters and the impact on synaptic function.

The Role of ADAMTSL3 in Synaptic Transmission

The regulation of synaptic plasticity by ADAMTSL3 is critical for the maintenance of neuronal communication and the formation of new synapses in the developing brain. Several studies have demonstrated that altered levels of ADAMTSL3 are associated with disruptions in synaptic plasticity and neurotransmission in various neurodegenerative diseases, including ALS-like synaptic transmission.

In ALS, the accumulation of neurotransmitter-associated protein (NAPP-GABA), a protein that interacts with GABA receptors, is thought to contribute to the pathological changes observed in this disease. The dysregulation of GABA signaling by ADAMTSL3 has been implicated in the pathogenesis of ALS-like synaptic transmission.

Drug Targeting ADAMTSL3

The study of ADAMTSL3 as a drug target has significant implications for the treatment of ALS-like synaptic transmission. Drugs that target ADAMTSL3 have been shown to improve synaptic plasticity and alleviate neurodegeneration in various animal models of ALS.

One such drug is Aducanumab, an anti-ADAMTSL3 antibody that has been shown to improve neurotransmission and protect against neurodegeneration in ALS-like models. Aducanumab has also been shown to cross the blood-brain barrier and target the intracranial ADAMTSL3 protein, suggesting that it may have a potential clinical impact on ALS.

Biomarkers for ALS-like Synaptic Transmission

The assessment of synaptic transmission is critical for the diagnosis and prognosis of ALS-like synaptic transmission. Several biomarkers, including neurotransmitter levels, have been shown to be affected by the dysfunction in synaptic transmission.

One such biomarker is the ratio of valproic acid (VPA) to GABA, a well-established neurotransmitter that can modulate synaptic transmission. The levels of VPA to GABA have been shown to be affected by disruptions in synaptic transmission, including changes in the levels of neurotransmitters and the dysfunction of the neurotransmitter receptor.

In addition to VPA/GABA, other biomarkers, including the levels of neurotransmitter-associated protein (NAPP-GABA), have also been shown to be affected by the dysfunction in synaptic transmission. The dysregulation

Protein Name: ADAMTS Like 3

The "ADAMTSL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAMTSL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets